title: Gastric plasma biomarkers and Operative Link for Gastritis Assessment gastritis stage.
abstract: BACKGROUND
  The Operative Link for Gastritis Assessment (OLGA) staging system has been proposed as a histopathological reporting system of gastric atrophy. Noninvasive methods for indirect evaluation of gastric mucosal atrophy by biomarkers are also being introduced.
  
  
  OBJECTIVE
  To analyze gastric mucosal atrophy by biomarkers, pepsinogen I (PgI), pepsinogen II (PgII), PgI/PgII ratio, fasting gastrin-17 (G-17), stimulated gastrin-17 (sG-17), in relation to OLGA gastritis stage.
  
  
  METHODS
  Gastric biopsies were taken from 269 prospective patients referred for upper endoscopy because of dyspeptic problems and evaluated by two expert pathologists (D.J. and P.S.). Atrophy was assessed according to the OLGA staging system. Pg I, PgII, Pg I/II, G-17, sG-17 were determined in a plasma sample.
  
  
  RESULTS
  The mean levels of PgI and PgI/PgII decreased significantly from 90.8 μg/l and 7.6 in stage 0 gastritis to 64.3 μg/l and 4.3 in high-stage gastritis. The mean values of G-17 and sG-17 were significantly higher among patients with stage II gastritis compared with stage 0 and high-stage gastritis.The proportion of patients with normal mucosa and nonatrophic gastritis according to biomarkers decreased from 78% in stage 0 to 22% in high-stage (III-IV) gastritis. Among the latter no case with normal mucosa, according to biomarkers, was observed.
  
  
  CONCLUSIONS
  A significant inverse correlation between the mean levels of PgI, PgI/II ratio and the OLGA stage was observed. Percentage of dyspeptic patients with normal mucosa, by blood biomarkers, decreased with increasing OLGA gastritis stages. OLGA staging system provides a good frame for scientific analysis of gastric mucosal atrophy.
authors.affiliation: University of Latvia, Riga, Latvia. ilva_daugule@hotmail.com
authors.forename: Ilva
authors.initials: I
authors.lastname: Daugule
authors.forename: Agnese
authors.initials: A
authors.lastname: Sudraba
authors.forename: Han-Mo
authors.initials: HM
authors.lastname: Chiu
authors.forename: Konrads
authors.initials: K
authors.lastname: Funka
authors.forename: Audrius
authors.initials: A
authors.lastname: Ivanauskas
authors.forename: Dainius
authors.initials: D
authors.lastname: Janciauskas
authors.forename: Laimas
authors.initials: L
authors.lastname: Jonaitis
authors.forename: Gediminas
authors.initials: G
authors.lastname: Kiudelis
authors.forename: Ivars
authors.initials: I
authors.lastname: Tolmanis
authors.forename: Aigars
authors.initials: A
authors.lastname: Vanags
authors.forename: Jaw-Town
authors.initials: JT
authors.lastname: Lin
authors.forename: Limas
authors.initials: L
authors.lastname: Kupcinskas
authors.forename: Marcis
authors.initials: M
authors.lastname: Leja
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood*; D005260:Female; D005755:Gastrins / Q000097:blood*; D005757:Gastritis, Atrophic / Q000097:blood* / Q000382:microbiology; D016481:Helicobacter Infections / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D020116:Pepsinogen A / Q000097:blood*; D020115:Pepsinogen C / Q000097:blood*; D011446:Prospective Studies
chemical_list: D015415:Biomarkers; D005755:Gastrins; D020115:Pepsinogen C; D020116:Pepsinogen A